Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

Symbio Pharmaceuticals / Equity Bottom-Up

<ul><li>Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn.</li><li>SG&A expenses increased by 12.7% YoY to JPY4.2bn, with R&D expenses rising 36.7% YoY to JPY2.5bn.</li><li>The company revised its FY12/24 forecast, projecting a full-year operating loss of JPY3.7bn and net loss of JPY3.6bn.</li></ul>

Sales decreased by 57.1% YoY to JPY1.9bn, with operating, recurring, and net losses each at JPY2.8bn.SG&A expenses increased by 12.7% YoY to JPY4.2bn, with R&D expenses rising 36.7% YoY to JPY2.5bn.The company revised its FY12/24 forecast, projecting a full-year operating loss of JPY3.7bn and net loss of JPY3.6bn.

Symbio Pharmaceuticals (4582 JP): Q3 FY12/24 flash update